Guardian Pharmacy Services Raises 2026 EBITDA Guidance on Strong 2025 Performance
Event summary
- Guardian Pharmacy Services reported Q4 2025 revenue of $397.6M, up 17% YoY with 12% organic growth.
- Residents served increased 10% YoY to approximately 205,000.
- Net income surged 81% YoY to $21.3M, with Adjusted EBITDA up 53% to $39.5M.
- Full-year 2025 revenue reached $1.45B, up 18% YoY, with Adjusted EBITDA at $115.1M.
- Company raised 2026 Adjusted EBITDA guidance to $120M–$124M from $115M–$118M.
The big picture
Guardian Pharmacy Services' strong 2025 performance reflects its scalable business model and disciplined investment strategy. The company's ability to raise 2026 EBITDA guidance underscores its confidence in long-term value creation, even as it navigates the initial phase of new IRA drug pricing changes. The acquisition of North Ridge Pharmacy further solidifies its position in the long-term care pharmacy services sector.
What we're watching
- Operational Scalability
- Whether Guardian can sustain its strong operational momentum amid IRA drug pricing changes.
- Payor Dynamics
- How favorable payor dynamics will impact future quarters beyond the fourth-quarter variability.
- Acquisition Strategy
- The pace at which Guardian integrates new acquisitions like North Ridge Pharmacy into its platform.
Related topics